BCRX — BIOCRYST PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 882796 ·
Last close
$10.45
Market Cap
$2.66B
52W High
$11.22
52W Low
$7.79
ADV30
5,589,721
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 156,413,000 | 151,036,000 | -701,598,000 | -721,812,000 | 465,052,000 | 171,591,000 | 1,018,895,000 |
| Dec 2025 | 406,555,000 | 397,033,000 | 260,385,000 | 245,845,000 | 514,158,000 | 89,736,000 | 633,311,000 |
| Sep 2025 | 159,395,000 | 157,208,000 | 29,591,000 | 12,899,000 | 446,424,000 | 84,078,000 | 834,313,000 |
| Jun 2025 | 163,353,000 | 160,555,000 | 29,786,000 | 5,085,000 | 457,188,000 | 88,033,000 | 878,782,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$347,369,000
Investing CF
$-13,694,000
Financing CF
$-349,931,000
CapEx
$-2,468,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$1.20
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,506,179,000
Inventory
$5,398,000
Receivables
$106,818,000
ST Investments
$185,011,000
EBIT TTM
$346,263,000
Pretax Income TTM
$267,391,000
Interest Exp TTM
$78,872,000
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$885,715,968
EBITDA
$326,456,992
Free Cash Flow
$264,383,248
Enterprise Value
$3,344,306,688
Total Cash
$238,400,000
Total Debt
$858,083,008
Shares Out
254,162,660
Trailing EPS
$-1.77
Book Value
$-2.18
ROE
—
ROA
42.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 874,837,000 | 340,989,000 | 263,861,000 | 514,158,000 | 633,311,000 | — | 347,369,000 |
| Dec 2024 | 450,712,000 | -2,543,000 | -88,881,000 | 490,420,000 | 966,354,000 | — | -52,020,000 |
| Dec 2023 | 331,412,000 | -103,709,000 | -226,539,000 | 516,960,000 | 972,488,000 | — | -95,141,000 |
| Dec 2022 | 270,827,000 | -148,435,000 | -247,116,000 | 550,000,000 | 844,597,000 | — | -161,850,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.93
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KOD | Kodiak Sciences Inc. | $2.59B | $41.31 | — |
| TARS | Tarsus Pharmaceuticals, Inc. | $2.54B | $58.14 | — |
| VCEL | Vericel Corp | $2.40B | $47.00 | — |
| ADMA | ADMA BIOLOGICS, INC. | $2.10B | $9.08 | — |
| BEAM | Beam Therapeutics Inc. | $3.36B | $32.68 | — |
News headlines (Yahoo Finance, 1h cache)
BioCryst (BCRX) Stock Looks Below Fair Value As Caution Lingers
2026-07-09 07:13 · Yahoo
Why Did PENG, ANET, BCRX Shares Surge To 52-Week Highs?
2026-07-09 03:39 · Yahoo
BioCryst Pharmaceuticals (BCRX) Ends Internal Discovery And Closes Birmingham Facility
2026-07-09 02:11 · Yahoo
BioCryst (BCRX) Surges 8.1%: Is This an Indication of Further Gains?
2026-07-08 14:14 · Yahoo
VKTX Vs BCRX: Which Biotech Takeover Favorite Offers More Upside After Vertex’s $10B CRNX Deal?
2026-07-08 05:11 · Yahoo
Why Did CRNX, D, BCRX Stocks Surge To 52-Week Highs Today?
2026-07-08 03:34 · Yahoo
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-02 11:00 · Yahoo
BioCryst to Discontinue Internal Discovery Programs, Close Birmingham Facility by Year-End
2026-06-29 12:06 · Yahoo
BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
2026-06-29 11:00 · Yahoo
BCRX Stock Set For Best Week In Over 3 Months – Retail Shifts Focus To This Crucial Breakout Level
2026-06-25 16:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.